Latest Oncology News

China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS Metastases

January 30, 2023

The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.

FDA Okays Guardant360 Test as CDx for Elacestrant in ESR1-mutated Breast Cancer

January 30, 2023

The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.

Physicians Discuss Potential of Frontline Triplet Regimens for RCC

January 27, 2023

During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.